Boswellia is an herbal extract from the Boswellia serrata tree that may help reduce inflammation.
May help with rheumatoid arthritis, inflammatory bowel disease, asthma, and cancer.
-Naturally occurring pentacyclic triterpenoids include ursolic acid (UA), oleanolic acid (OA), betulinic acid (BetA), bosewellic acid (BA), Asiatic acid (AA), α-amyrin, celastrol, glycyrrhizin, 18-β-glycyrrhetinic acid, lupeol, escin, madecassic acid, momordin I, platycodon D, pristimerin, saikosaponins, soyasapogenol B, and avicin
Boswellia refers to a group of resinous extracts obtained from Boswellia trees (e.g., Boswellia serrata). Traditionally used in Ayurvedic and traditional Chinese medicine, Boswellia is reputed for its anti-inflammatory, analgesic, and immunomodulatory properties. Its bioactive components—such as boswellic acids.
Boswellic acids belong to the pentacyclic triterpenoid class (a broader chemical family that includes compounds such as ursolic acid and betulinic acid found in other plants)
3-acetyl-11-keto-β-boswellic acid (AKBA)
11-keto-β-boswellic acid (KBA)
α-boswellic acid (αBA)
β-boswellic acid (βBA)
3-acetyl-α-boswellic acid (AαBA)
3-acetyl-β-boswellic acid (AβBA)
-Anti-inflammatory Activity (blocking the enzyme 5-lipoxygenase)
5LOX↓,.
-AKBA inhibits
methionine adenosyltransferase 2A (MAT2A)***** (help in Methionine reduced diet?)
Boswellia extracts are often administered in doses ranging from 300 mg to 1,200 mg per day
AKBA (Acetyl-11-keto-β-boswellic acid) is a bioactive compound derived from Boswellia serrata, a plant used traditionally for its anti-inflammatory properties. (upto 30% AKBA in
Boswellia MEGA AKBA)
AKBA also available in Inflasanum @ 90% AKDA (MCSformulas)
-Note half-life reports vary 2.5-90hrs?.
BioAv (bio availability increases with high fat meal)
Pathways:
- induce or lower
ROS production (not consistant increase for cancer cells)
- ROS↑ related:
MMP↓(ΔΨm),
ER Stress↑,
GRP78↑,
Ca+2↑,
Cyt‑c↑,
Caspases↑,
DNA damage↑,
cl-PARP↑,
- may Raise
AntiOxidant
defense in Normal Cells:
ROS↓,
NRF2↑,
SOD↑,
GSH↑,
Catalase↑,
- lowers
Inflammation :
NF-kB↓,
COX2↓,
p38↓
(context-dependent; stress/inflammatory MAPK modulation), Pro-Inflammatory Cytokines :
IL-1β↓,
TNF-α↓,
IL-6↓,
- inhibit Growth/Metastases :
,
MMPs↓,
MMP2↓,
MMP9↓,
VEGF↓,
NF-κB↓,
CXCR4↓,
ERK↓
- cause Cell cycle arrest :
TumCCA↑,
cyclin D1↓,
cyclin E↓,
CDK2↓,
CDK4↓,
CDK6↓,
- inhibits Migration/Invasion :
TumCMig↓,
TumCI↓,
ERK↓,
TOP1↓,
- inhibits
angiogenesis↓ :
VEGF↓,
NOTCH">Notch↓,
PDGF↓,
- Others: PI3K↓,
AKT↓,
STAT↓,
Wnt↓,
β-catenin↓,
AMPK↓,
ERK↓,
JNK(JNK is activated under stress)
- Synergies:
chemo-sensitization,
chemoProtective,
RadioProtective,
Others(review target notes),
Neuroprotective,
Cognitive,
Hepatoprotective,
- Selectivity:
Cancer Cells vs Normal Cells
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
NF-κB axis (IKK → NF-κB; NF-κB-regulated genes) |
NF-κB ↓; downstream targets ↓ (COX-2, Cyclin D1, Bcl-2/Bcl-xL/IAPs, MMP-9, VEGF, CXCR4 etc.) |
Anti-inflammatory tone (context) |
R, G |
Anti-survival / anti-inflammatory transcription |
AKBA-class compounds suppress NF-κB signaling and reduce multiple NF-κB-regulated tumor programs in vitro and in vivo models. |
| 2 |
5-LOX (leukotriene pathway) / eicosanoid signaling |
5-LOX activity ↓ (context); pro-inflammatory eicosanoid signaling ↓ |
Anti-inflammatory support |
P, R |
Direct enzymatic / lipid-mediator suppression |
Boswellic acids are widely discussed as 5-LOX–linked anti-inflammatory agents; cancer relevance often tracks inflammation-driven growth signals. |
| 3 |
Apoptosis (extrinsic + intrinsic; caspases; PARP) |
Apoptosis ↑; Caspase-8/3 ↑; cl-PARP ↑ (context) |
↔ |
G |
Cell death execution |
Reported apoptosis induction includes death-receptor (e.g., DR5-associated) and caspase/PARP cleavage patterns in multiple tumor models. |
| 4 |
Cell-cycle control (Cyclin D1 / checkpoints) |
Cyclin D1 ↓; proliferation ↓; arrest ↑ (context) |
↔ |
G |
Cytostasis |
Often presented as downstream of NF-κB/survival signaling suppression and stress adaptation. |
| 5 |
Invasion / metastasis programs (MMP-9, ICAM-1, CXCR4) |
Invasion markers ↓; MMP-9 ↓; ICAM-1 ↓; CXCR4 ↓ (context) |
↔ |
G |
Anti-invasive phenotype |
In vivo tumor models report reductions in invasive and chemokine/migration biomarkers alongside NF-κB suppression. |
| 6 |
Angiogenesis signaling (VEGF; VEGFR2-mediated angiogenesis) |
VEGF ↓; angiogenic outputs ↓ (context) |
↔ |
G |
Anti-angiogenic support |
AKBA has been reported to suppress angiogenesis programs including VEGF signaling, with VEGFR2-mediated angiogenesis discussed in prostate cancer contexts. |
| 7 |
PI3K → AKT (± mTOR) survival axis |
PI3K/AKT ↓ (reported; model-dependent) |
↔ |
R, G |
Growth/survival suppression |
Commonly listed as a downstream survival pathway impacted by boswellic acids; keep as “reported” (not universal across all models). |
| 8 |
MAPK re-wiring (ERK / JNK / p38) |
Stress-MAPK modulation (context-dependent) |
↔ |
P, R, G |
Signal reprogramming |
MAPK direction varies by tumor type/dose and whether the experimental system is inflammatory vs cytotoxic. |
| 9 |
Chemo-/radio-sensitization (combination relevance) |
Sensitization ↑ (context) |
— |
G |
Combination leverage |
Combination studies report enhanced tumor control when AKBA-class compounds are paired with other therapies (context and regimen dependent). |
| 10 |
Bioavailability constraint (oral exposure; formulation dependence) |
Systemic exposure often limited without enhanced delivery |
— |
— |
Translation constraint |
Poor pharmacokinetics are a common limitation; multiple strategies (e.g., micellar delivery, bioenhancers) are studied to improve absorption. |
Time-Scale Flag (TSF): P / R / G
- P: 0–30 min (primary/physical–chemical effects; rapid enzymatic/kinase shifts)
- R: 30 min–3 hr (acute redox + stress-response signaling)
- G: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)
|